Özgür BAYKAN, Elif AKSÖZ, Medine KARABULUT

Age-related differences in the effect of vitamin D onscopolamine-induced learning and memory impairment

Aim: Alzheimer's disease is the most common type of dementia. The number of patients with Alzheimer's is expected to reach 115million in 2050. Due to the low effectiveness and frequent adverse effects of current treatment approaches, expected results cannotbe obtained in treatment. Vitamin D supplements are reported to have protective effects against Alzheimer's disease by increasinglearning and memory performance. In this study, we aimed to evaluate the effect of vitamin D on learning and memory on cognitivedeficits by scopolamine-induced memory impairment model, which is an animal model of AD, in aged rats, as well as evaluatingwhether the effect changes with age.Materials and Methods: Wistar Albino male rats (Young: 4-5 months old, Aged: 21-22 months old) were used in the study. VitaminD was given for three weeks at 500 IU/kg; scopolamine was applied 1mg/kg half an hour before behavioral experiments. Modifiedelevated plus maze and Morris water maze tests was performed to assess cognitive abilities during the fourth week; prefrontalcortices were then removed to assess acetylcholinesterase enzyme activity. Results: Vitamin D administration restored memory impairment in old rats in the Morris water maze; whereas there was no effect inyoung group. Scopolamine significantly increased the brain prefrontal cortex AchE enzyme activity only in the young rats. Vitamin Ddid not create a statistically significant change in AChE activity in young rats. on the other hand, a significant increase was detectedin the elderly group with vitamin D compared to the age-matched control and scopolamine groups. Conclusion: Our results show that the effectiveness of vitamin D changes with age. Vitamin D may be a safe and effective option inpreventing dementia development in the elderly group and improving cognitive dysfunction due to Alzheimer's disease.

PDF

___

1. Qiu C, Kivipelto M, von Strauss E. Epidemiology of Alzheimer’s disease: occurrence, determinants, and strategies toward intervention. Dialogues Clin Neurosci 2009;11:111-28.
2. International. AD. World Alzheimer Report 2019: Attitudes to Dementia 2019. https://www.alz.co.uk/ research/WorldAlzheimerReport2019.pdf
3. Auld DS, Kornecook TJ, Bastianetto S, et al. Alzheimer’s disease and the basal forebrain cholinergic system: relations to beta-amyloid peptides, cognition, and treatment strategies. Prog Neurobiol 2002;68:209-45.
4. Khoury R, Patel K, Gold J, et al. Recent Progress in the Pharmacotherapy of Alzheimer ’ s Disease. Drugs Aging 2018;34:811-20.
5. Balion C, Griffith LE, Strifler L, et al. Vitamin D, cognition , and dementia A systematic review and meta-analysis. Neurology 2012;79:1397-405.
6. Eyles DW, Smith S, Kinobe R, et al. Distribution of the vitamin D receptor and 1 alpha-hydroxylase in human brain. J Chem Neuroanat 2005;29:21-30.
7. Farghali M, Ruga S, Morsanuto V, et al. Can Brain Health Be Supported by Vitamin D-Based Supplements ? A Critical Review. Brain Sci 2020;10:660.
8. Lips P, van Schoor NM, de Jongh RT. Diet, sun, and lifestyle as determinants of vitamin D status. Ann N Y Acad Sci 2014;1317:92-8.
9. Holick MF. Vitamin D deficiency. N Engl J Med 2007;357:266-81.
10. Klinkenberg I, Blokland A. The validity of scopolamine as a pharmacological model for cognitive impairment: A review of animal behavioral studies. Neurosci Biobehav Rev 2010;34:1307-50.
11. Alrefaie Z. Vitamin D 3 improves decline in cognitive function and cholinergic transmission in prefrontal cortex of streptozotocin-induced diabetic rats. Behav Brain Res 2015;287:156-62.
12. Khairy EY, Attia MM. Protective effects of vitamin D on neurophysiologic alterations in brain aging : role of brain-derived neurotrophic factor ( BDNF ). Nutr Neurosci 2019;0:1-10.
13. Aksoz E, Gocmez SS, Sahin TD, et al. The protective effect of metformin in scopolamine-induced learning and memory impairment in rats. Pharmacol Reports 2019;71:818-825.
14. Randall RJ, Lewis A. Protein measurement with Folin Phenol reagent. J Biol Chem 1951;193:265-75.
15. Hliák Z, Krejčí I. MK-801 induced amnesia for the elevated plus-maze in mice. Behav Brain Res 2002;131:221-5.
16. Zhang X. Cholinergic activity and amyloid precursor protein processing in aging and Alzheimer ’ s disease. Curr Drug Targets CNS Neurol Disord 2004;3:137-152.
17. Barnes CA, Meltzer J, Houston F, et al. Chronic treatment of old rats with donepezil or galantamine: effects on memory, hippocampal plasticity and nicotinic receptors. Neuroscience 2000;99:17-23.
18. Scali B, Scali C, Giovannini MG, et al. Effect of metrifonate on extracellular brain acetylcholine and object recognition in aged rats. Eur J Pharmacol 1997;325:173-80.
19. Rani PJ, Panneerselvam C. Protective efficacy of L-carnitine on acetylcholinesterase activity in aged rat brain. J Gerontol A Biol Sci Med Sci 2001;56:B140- 1.
20. Sonnenberg J, Luine VN, Krey LC, et al. 1,25-Dihydroxyvitamin D3 treatment results in increased choline acetyltransferase activity in specific brain nuclei. Endocrinology 1986;118:1433-9.
21. Musiol IM, Stumpf WE, Bidmon HJ, et al. Vitamin D nuclear binding to neurons of the septal, substriatal and amygdaloid area in the Siberian hamster (Phodopus sungorus) brain. Neuroscience 1992;48:841-8.
22. Taghizadeh M, Talaei SA, Salami M. Vitamin D deficiency impairs spatial learning in adult rats. Iran Biomed J 2013;17:42-8.
23. Taghizadeh M, Djazayery A, Salami M, et al. VitaminD-free regimen intensifies the spatial learning deficit in Alzheimer's disease. Int J Neurosci 2011;121:16- 24.Briones TL, Darwish H. Vitamin D mitigates agerelated cognitive decline through the modulation of pro-inflammatory state and decrease in amyloid burden. J Neuroinflammation 2012;9:244.
24. Latimer CS, Brewer LD, Searcy JL, et al. Vitamin D prevents cognitive decline and enhances hippocampal synaptic function in aging rats. Proc Natl Acad Sci U S A 2014;111:E4359-66.
25. Briones TL, Darwish H. Vitamin D mitigates agerelated cognitive decline through the modulation of pro-inflammatory state and decrease in amyloid burden. J Neuroinflammation 2012;9:244.
26. Itoh J, Nabeshima T, Kameyama T. Utility of an elevated plus-maze for the evaluation of memory in mice: effects of nootropics, scopolamine and electroconvulsive shock. Psychopharmacology (Berl) 1990;101:27-33.
27. Kruk-Słomka M, Budzyńska B, Biała G. Involvement of cholinergic receptors in the different stages of memory measured in the modified elevated plus maze test in mice. Pharmacol Rep 2012;64:1066-80.
28. Rodrigues MV, Gutierres JM, Carvalho F, et al. Protection of cholinergic and antioxidant system contributes to the effect of Vitamin D 3 ameliorating memory dysfunction in sporadic dementia of Alzheimer ’ s type. Redox Rep 2019;0002:1-8.
29. Paul R, Borah A. Global loss of acetylcholinesterase activity with mitochondrial complexes inhibition and inflammation in brain of hypercholesterolemic mice. Sci Rep 2017;7:1-13.
30. García-Ayllón MS, Riba-Llena I, Serra-Basante C, et al. Altered Levels of Acetylcholinesterase in Alzheimer Plasma. PLoS One 2010;5:e8701.